Cargando…

Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study

BACKGROUND: Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) occurs in some patients receiving ART experience, especially increases in those patients with intermittent or persiste...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Yun, Ling, Xuemei, Deng, Xizi, Lin, Yaqing, Li, Junbin, Li, Liya, He, Ruiying, Cai, Weiping, Li, Feng, Li, Linghua, Hu, Fengyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402888/
https://www.ncbi.nlm.nih.gov/pubmed/37546367
http://dx.doi.org/10.2147/IDR.S419610
_version_ 1785084941430685696
author Lan, Yun
Ling, Xuemei
Deng, Xizi
Lin, Yaqing
Li, Junbin
Li, Liya
He, Ruiying
Cai, Weiping
Li, Feng
Li, Linghua
Hu, Fengyu
author_facet Lan, Yun
Ling, Xuemei
Deng, Xizi
Lin, Yaqing
Li, Junbin
Li, Liya
He, Ruiying
Cai, Weiping
Li, Feng
Li, Linghua
Hu, Fengyu
author_sort Lan, Yun
collection PubMed
description BACKGROUND: Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) occurs in some patients receiving ART experience, especially increases in those patients with intermittent or persistent low-level viremia (LLV). The presence of drug resistance mutations (DRMs) in LLV was a strong predictor of subsequent VF. The data on drug resistance (DR) or DRMs for HIV-1 infections at low-level viral load (LLVL) are limited in China. OBJECTIVE: To monitor the prevalence of HIV-1 drug resistance and to evaluate the risk factors associated with drug resistance in LLVL HIV-1 infections during ART in Guangdong, China. METHODS: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing. Then, the genotypic resistance test was performed and DR was analyzed by the Stanford HIVDB program. Finally, DR-associated factors were identified by logistic regression analysis. RESULTS: We found that CRF01_AE (53.57%) and CRF07_BC (25.07%) were the dominant HIV-1 genotypes in LLVL in Guangdong between 2011 and 2022 but that the percentage of CRF01_AE showed a trend of decrease over time. M46 (1.49%), M184 (30.91%), and K103 (21.46%) were the dominant PI-, NRTI-, and NNRTI-associated mutations, respectively. The total DR rate was 47.06%. Specifically, PI (3.71%) showed a significantly lower DR rate than NNRTI (40.74%) and NRTI (34.14%). Duration of ART, initial ART regimen, ethnicity, and WHO clinical stages were associated with DR. CONCLUSION: The drug resistance rate among the LLVL during ART in Guangdong, China is high. The risk factors associated with HIV drug resistance should be seriously considered for better control.
format Online
Article
Text
id pubmed-10402888
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104028882023-08-05 Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study Lan, Yun Ling, Xuemei Deng, Xizi Lin, Yaqing Li, Junbin Li, Liya He, Ruiying Cai, Weiping Li, Feng Li, Linghua Hu, Fengyu Infect Drug Resist Original Research BACKGROUND: Antiretroviral therapy (ART) efficiently reduces the morbidities and mortalities caused by HIV-1 infection and prevents the HIV epidemic. However, virologic failure (VF) occurs in some patients receiving ART experience, especially increases in those patients with intermittent or persistent low-level viremia (LLV). The presence of drug resistance mutations (DRMs) in LLV was a strong predictor of subsequent VF. The data on drug resistance (DR) or DRMs for HIV-1 infections at low-level viral load (LLVL) are limited in China. OBJECTIVE: To monitor the prevalence of HIV-1 drug resistance and to evaluate the risk factors associated with drug resistance in LLVL HIV-1 infections during ART in Guangdong, China. METHODS: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing. Then, the genotypic resistance test was performed and DR was analyzed by the Stanford HIVDB program. Finally, DR-associated factors were identified by logistic regression analysis. RESULTS: We found that CRF01_AE (53.57%) and CRF07_BC (25.07%) were the dominant HIV-1 genotypes in LLVL in Guangdong between 2011 and 2022 but that the percentage of CRF01_AE showed a trend of decrease over time. M46 (1.49%), M184 (30.91%), and K103 (21.46%) were the dominant PI-, NRTI-, and NNRTI-associated mutations, respectively. The total DR rate was 47.06%. Specifically, PI (3.71%) showed a significantly lower DR rate than NNRTI (40.74%) and NRTI (34.14%). Duration of ART, initial ART regimen, ethnicity, and WHO clinical stages were associated with DR. CONCLUSION: The drug resistance rate among the LLVL during ART in Guangdong, China is high. The risk factors associated with HIV drug resistance should be seriously considered for better control. Dove 2023-07-31 /pmc/articles/PMC10402888/ /pubmed/37546367 http://dx.doi.org/10.2147/IDR.S419610 Text en © 2023 Lan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lan, Yun
Ling, Xuemei
Deng, Xizi
Lin, Yaqing
Li, Junbin
Li, Liya
He, Ruiying
Cai, Weiping
Li, Feng
Li, Linghua
Hu, Fengyu
Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study
title Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study
title_full Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study
title_fullStr Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study
title_full_unstemmed Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study
title_short Drug Resistance Profile Among HIV-1 Infections Experiencing ART with Low-Level Viral Load in Guangdong China During 2011–2022: A Retrospective Study
title_sort drug resistance profile among hiv-1 infections experiencing art with low-level viral load in guangdong china during 2011–2022: a retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402888/
https://www.ncbi.nlm.nih.gov/pubmed/37546367
http://dx.doi.org/10.2147/IDR.S419610
work_keys_str_mv AT lanyun drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT lingxuemei drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT dengxizi drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT linyaqing drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT lijunbin drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT liliya drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT heruiying drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT caiweiping drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT lifeng drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT lilinghua drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy
AT hufengyu drugresistanceprofileamonghiv1infectionsexperiencingartwithlowlevelviralloadinguangdongchinaduring20112022aretrospectivestudy